Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Resectable Hepatocellular CarcinomaMacrovascular InvasionCNLC IIIA Stage
Interventions
DRUG

Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab

"SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg,3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT."

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06524466 - Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter